Correlation Between Copeptin and PSI with Intravenous to Oral Antibiotic Switch Theraphy and Length of Stay in Community-Acquired Pneumonia
DOI:
https://doi.org/10.36497/jri.v39i1.40Keywords:
Community Acquired Pneumonia, Copeptin, PSI Score, Switch Theraphy, Length of StayAbstract
Background: Pneumonia is a world’s health problem. AVP level in the circulation is difficult to measure therefore copeptin is chosen since it is more comparable in number and more stable. Method: Prospective observational study on 25 patients with community-acquired pneumonia in Dr.Moewardi Hospital from July-August 2017. Result: There were no significant differences between switch therapy duration and length of stay to subject’s characteristic. There was a positive and significant correlation of PSI score to switch therapy and length of stay with a medium to strong correlation strength. Copeptin to switch therapy and length of stay had a positive and significant correlation with a medium to strong correlation strength. Pneumonia patients with PSI Score >90 had a risk of 36.67 times higher with switch therapy duration >4 days and it could be used as a predictor of switch therapy duration. Copeptin >17.23 with switch theraphy duration >4 days on pneumonia patient had a risk of 24.75 times higher and it could be used as a predictor of switch therapy duration. Pneumonia’s patient with PSI Score >100 with length of stay >10 days had a risk of 26.00 times higher and it could be used as a predictor of length of stay. Copeptin >27.39 with length of stay >10 days on pneumonia’s patient had a risk of 36.00 times higher and it could be used as a predictor of length of stay. Conclusion: Both PSI Score and copeptin level had positive and significant correlation to switch theraphy and length of stay. (J Respir Indo 2019; 39(1): 44-53)Downloads
References
Engel MF, Postma DF, Hulscher ME, Teding van berkhout F, Emmelot-Vonk MH, Sankatsing S, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J. 2013;41(1):123-30.
Tores A, Menendez R, Wunderink RG. Bacterial pneumonia and lung abcess. In: Mason RJ, Ernst JD, King TE, Lazrus S, Murray JF, Nadel JA, et al, editors. Murray & Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier; 2016. p.557-82.
Rofiq A, Karyana M, Azhar K, Syarif AK, Indah RM. Penyakit menular. In: Riset kesehatan dasar 2013. p. 65-71.
Mizgerd JP. Acute lower respiratory tract infection. N Engl J Med. 2008;358(7):716-27.
Stoeckel DA, Matuschak GM. Management of pneumonias. In: Lechner AJ, Matuschak GM, Brink DS, editors. Respiratory an integrated approach to disease. 1st ed. New York: Mc Graw Hill; 2011. p.345-53.
Mattila JT, Fine MJ, Limper AH, Murray PR, Chen BB, Lin PL. Pneumonia: treatment and diagnosis. Ann Am Thorac Soc. 2014;11:S189-92.
Marrie TJ. Community acquired pneumonia: clinical features and outcomes. In: Marrie TJ, editor. Communityacquired pneumonia. 1st ed. Canada: Kluwer’s; 2002. p.29-33.
Qu JM, Summah H. Biomarkers: a definite plus in pneumonia. Mediators Inflamm. 2009;2009:675753.
Christ-Crain M, Opal SM. Clinical review: the role of biomarkers in the diagnosis and management of communityacquired pneumonia. Crit Care. 2010;14:203.
Nickel CH, Bingisser R, Morgenthaler NG. The role of copeptin as a diagnostic and prognostic biomarker for risk stratification in the emergency department. BMC Med. 2012;10:7.
Itoi K, Jiang YQ, Iwasaki Y, Watson SJ. Regulatory mechanisms of corticotropin-releasing hormone and vasopressin gene expression in the hypothalamus. J Neuroendocrinol. 2004;16(4):348-55.
Ratnayake U, Quinn T, Walker DW, Dickinson H. Cytokines and the neurodevelopmental basis of mental illness. Front Neurosci. 2013;7:1-9.
Dobsa L, Edozien KC. Copeptin and its potential role in diagnosis and prognosis of various diseases. Biochem Med (Zagreb). 2013;23(2):172-90.
Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem. 2006;52(1):112-9.
Aliberti S, Giuliani F, Ramirez J, Blasi F. How to choose the duration of antibiotic therapy in patients with pneumonia. Curr Opin Infect Dis. 2015;28(2):177-84.
Ramirez JA. Switch therapy in communityacquired pneumonia. Diagn Microbiol Infect Dis. 1995;22(1-2):219-23.
Perhimpunan Dokter Paru Indonesia. Pneumonia komunitas. Pedoman diagnosis dan penatalaksanaan di Indonesia. Balai Penerbit FKUI. Jakarta. 2014.
Dewantara A, Suradi, Reviono, Rima A, Harsini, Aphridasari J. Pengaruh pemberian zink selama 5 hari terhadap kadar endothelin-1, tumor necrosis factor-α dan perbaikan klinis penderita pneumonia. J Respir Indo. 2017;37:8-14.
Menendez R, Zalacain R, Torres A, Cellis R, Esteban L, Blanguer R, et al. Community- acquiered pneumonia in the elderly: Spanish multicenter study. Eur Respir J. 2003;21(2):294-302.
Engel MF, Postma D, Hulscher ME, Teding van Berkhout F, Emmelet-Vonk MH, Sankatsing S, et al. Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP. Eur Respir J. 2013;41(1):123-130.
Müller B, Morgenthaler N, Stolz D, Schuetz P, Müller C, Bingisser R, et al. Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infections. Eur J Clin Invest. 2007;37(2):145-52.
Woodhead M. Treatment of communityacquired pneumonia. In: Marrie TJ, editor. Community-acquired pneumonia. 1st ed. Canada: Kluwer’s; 2002. p.163-75.
CastroGuardiola A, VieljoRodriguez AL, Soler Simon S, Armengou-Arxé A, Bisne-Company V, PeñarrojaMatutano G, et al. Efficacy and safety of oral and early-switch therapy for community acquired pneumonia: a randomized controlled trial. Am J Med. 2001;111(5):367-74.
Nathwani D, Lawson W, Dryden M, Stephens J, Corman S, Solem C, et all. Implementing criteria- based early switch/early discharge programmes: a European perspective. Clin Microbiol Infect. 2015;21:S47-55.
Katan M, Müller B, Christ-Crain M. Copeptin: a new and promising diagnostic and prognostic marker. Crit Care. 2008;12(2):111-7.
Elshafei A, Abdalla G, ElMotaal OA, Salman T. Copeptin: a neuroendocrine biomarker in acute myocardial infarction. Annu Res Rev Biol. 2013;3(4):1040-54.
Seligman R, Ramos-Lima LF, Oliveira Vdo A, Sanvicente C, Pacheco EF, Dalla Rosa K. Biomarkers in communityacquired pneumonia : a state-of-the-art review. Clinics (Sao Paulo). 2012;67(11):1321-5.
Abdel-Fattah M, Meligy B, El-Sayed R, El- Naga YA. Serum copeptin level as a predictor of outcome in pneumonia. Indian Pediatr. 2015;52(9):807-8.
Bolignano D, Cabassi A, Fiaccadori E, Ghigo E, Pasquali R, Peracino A, et al. Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med. 2014;52(10):1447-56.
Marrie TJ. Acute bronchitis and community- acquired pneumonia. In: Fishman AP, Jack AE, Jay AF, Michael AG, Robert MS, Allan IP, editors. Fishman’s pulmonary diseases and disorders. 5th ed. New York: McGrawHill Medical; 2008. p.1966-81.
Downloads
Additional Files
Published
Issue
Section
License
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
